Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Neoplasm Metastasis × Cetuximab × Clear all

Phase

Phase 2 29 Phase 1 16 Phase 1/2 6 Phase 3 5 Phase 4 2 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 3 Oropharyngeal Neoplasms 2 Mouth Neoplasms 2 Laryngeal Neoplasms 2 Hypopharyngeal Neoplasms 2 Colonic Neoplasms 2 Carcinoma 2 Rectal Neoplasms 1 Neoplasm Metastasis 1 Nasopharyngeal Carcinoma 1 Lymphoid Interstitial Pneumonia 1 Esophageal Squamous Cell Carcinoma 1 Esophageal Neoplasms 1 Adenocarcinoma Of Esophagus 1

Interventions

Gemcitabine 5 Capecitabine 4 pembrolizumab 3 Fluorouracil 3 Cisplatin 3 vinflunine 2 cabazitaxel 2 Ipilimumab 2 Haloperidol 2 trifluridine tipiracil drug combination 1 racemetyrosine 1 nimotuzumab 1 futibatinib 1 exemestane 1 enzalutamide 1 dexamethasone acetate 1 dexamethasone 21-phosphate 1 beta-Glucans 1 auricularum 1 atezolizumab 1 apatinib 1 abiraterone 1 XELOX 1 Water 1 Waiting Lists 1 Taxes 1 Tamoxifen 1 Sunitinib 1 Starch 1 Sirolimus 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03031444 2021-02-01

PARECEC

Peking University Cancer Hospital & Institute

Phase 2/3 Completed

Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡